Speed to transplant physician consult and transplant
| Variable . | Group . | N . | Median (IQR): indication to consult, d . | Median (IQR): consult to transplant, d . | Median (IQR): CR to transplant, d . | Median (IQR): indication to transplant, d . |
|---|---|---|---|---|---|---|
| Age, y | ≤56 | 160 | 44 (20-65) | 78 (62-106) | 72 (36-100) | 121 (99-162) |
| >56 | 153 | 41 (18-67) | 90 (66-122) | 76 (37-112) | 139 (108-189) | |
| Sex | Male | 163 | 42 (19-66) | 83 (64-121) | 76 (41-107) | 127 (107-172) |
| Female | 150 | 45 (18-66) | 84 (64-115) | 70 (35-102) | 126 (101-178) | |
| Ancestry∗ | European | 214 | 40 (17-65) | 82 (63-105) | 70 (36-96) | 121 (104-159) |
| Non-European | 99 | 48 (27-82) | 87 (69-130) | 86 (38-140) | 145 (114-214) | |
| ELN 2017 risk13 | Intermediate/favorable | 228 | 46 (20-74) | 80 (63-115) | 74 (36-112) | 129 (103-168) |
| Adverse | 85 | 37 (17-55) | 90 (71-115) | 71 (40-99) | 126 (106-182) | |
| HCT-CI | 0-2 | 183 | 45 (19-67) | 82 (64-114) | 71 (36-102) | 124 (105-163) |
| 3+ | 130 | 39 (18-64) | 87 (65-121) | 78 (38-112) | 130 (107-192) | |
| Graft source | HLA-identical sibling | 67 | 33 (18-65) | 77 (64-107) | 56 (35-89) | 119 (101-145) |
| 8/8 URD | 149 | 43 (19-63) | 86 (69-119) | 80 (41-114) | 139 (107-177) | |
| CB | 69 | 46 (29-67) | 73 (57-93) | 55 (31-92) | 121 (93-155) | |
| Haploidentical | 17 | 55 (19-71) | 128 (76-212) | 92 (66-165) | 208 (120-271) | |
| mmURD | 11 | 25 (15-102) | 122 (80-147) | 106 (72-154) | 154 (123-202) | |
| Referral type | Internal | 199 | 32 (15-55) | 90 (65-128) | 64 (35-97) | 124 (104-174) |
| External | 114 | 60 (37-89) | 77 (58-94) | 86 (52-130) | 133 (108-178) | |
| Period | Prepandemic | 260 | 46 (20-66) | 82 (63-115) | 74 (37-104) | 127 (105-177) |
| Pandemic | 53 | 32 (16-66) | 86 (74-113) | 72 (35-113) | 131 (108-168) |
| Variable . | Group . | N . | Median (IQR): indication to consult, d . | Median (IQR): consult to transplant, d . | Median (IQR): CR to transplant, d . | Median (IQR): indication to transplant, d . |
|---|---|---|---|---|---|---|
| Age, y | ≤56 | 160 | 44 (20-65) | 78 (62-106) | 72 (36-100) | 121 (99-162) |
| >56 | 153 | 41 (18-67) | 90 (66-122) | 76 (37-112) | 139 (108-189) | |
| Sex | Male | 163 | 42 (19-66) | 83 (64-121) | 76 (41-107) | 127 (107-172) |
| Female | 150 | 45 (18-66) | 84 (64-115) | 70 (35-102) | 126 (101-178) | |
| Ancestry∗ | European | 214 | 40 (17-65) | 82 (63-105) | 70 (36-96) | 121 (104-159) |
| Non-European | 99 | 48 (27-82) | 87 (69-130) | 86 (38-140) | 145 (114-214) | |
| ELN 2017 risk13 | Intermediate/favorable | 228 | 46 (20-74) | 80 (63-115) | 74 (36-112) | 129 (103-168) |
| Adverse | 85 | 37 (17-55) | 90 (71-115) | 71 (40-99) | 126 (106-182) | |
| HCT-CI | 0-2 | 183 | 45 (19-67) | 82 (64-114) | 71 (36-102) | 124 (105-163) |
| 3+ | 130 | 39 (18-64) | 87 (65-121) | 78 (38-112) | 130 (107-192) | |
| Graft source | HLA-identical sibling | 67 | 33 (18-65) | 77 (64-107) | 56 (35-89) | 119 (101-145) |
| 8/8 URD | 149 | 43 (19-63) | 86 (69-119) | 80 (41-114) | 139 (107-177) | |
| CB | 69 | 46 (29-67) | 73 (57-93) | 55 (31-92) | 121 (93-155) | |
| Haploidentical | 17 | 55 (19-71) | 128 (76-212) | 92 (66-165) | 208 (120-271) | |
| mmURD | 11 | 25 (15-102) | 122 (80-147) | 106 (72-154) | 154 (123-202) | |
| Referral type | Internal | 199 | 32 (15-55) | 90 (65-128) | 64 (35-97) | 124 (104-174) |
| External | 114 | 60 (37-89) | 77 (58-94) | 86 (52-130) | 133 (108-178) | |
| Period | Prepandemic | 260 | 46 (20-66) | 82 (63-115) | 74 (37-104) | 127 (105-177) |
| Pandemic | 53 | 32 (16-66) | 86 (74-113) | 72 (35-113) | 131 (108-168) |
Median time (IQR) from transplant indication to transplant was 160 (123-241) days for White Hispanic, 150 (121-237) days for African, and 119 (98-168) days for Asian-ancestry patients.